Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
aboutProlacriaand, abuse, Academy, adherence, Alacrity, Allegan, Allergology, anAzaSite, anAzaSiteapproval, anAzaSiteFDA, andAllegra, andAzopt®andTravatan®by, andCiloxan, andClaritin, andElestatwill, andOcuflox, andPataday, andPatanol, andProlacria, andQuixin, andTobryaDex, annum, approveAzaSite, approveProlacria, aspect, asserting, Asthma, Austria, automatically, AzaSite, AzaSitelaunch, azithromycin, bacterial, Bausch, Belize, bilastine, BioPharma, Blvd, borrow, borrowed, borrowing, BothPataday, broadly, bulbar, CAC, Canadian, cardiac, cedar, CFTR, Chemedica, ciclesonide, cigarette, commercializeAzaSite, commercializeProlacriaworldwide, congestion, conjunctival, constant, construed, Contemporaneously, Costa, coveringElestatwill, crossover, currentElestat, customary, cytoskeletal, depositary, depository, developingProlacria, dialogue, discharge, disciplinary, discount, disgorgement, distributor, dollar, doxycycline, eitherAzaSite, El, eleven, EMEA, enzyme, erythromycin, eventAzaSite, eventProlacria, expressed, Farma, forAzaSite, forElestatand, forElestatandRestasisbeginning, forfeited, forfeiture, formulary, forProlacria, forProlacriaand, forProlacriafor, fraud, fromProlacria, gentamycin, graft, grown, Guatemala, headcount, history, honest, hutson, hyaluronate, idiopathic, ifazasite, ifProlacria, Immunology, impede, imposition, inAzaSite, includeVigamox, includeXyzal, includeZyrtec, inclusion, incremental, injunctive, InSite, irrevocable, Justice, launchedPataday, lending, levocetirizine, loan, Lomb, lowest, Lynch, lysine, margin, marketingProlacria, Merrill, misconduct, mitigating, ml, motion, mountain, multiplied, nameZithromax, nancy, Nicaragua, noncompliance, nonexclusive, nose, notification, ofAzaSite, ofAzaSiteand, ofAzaSitefor, ofAzaSiteTM, ofBronchitolTM, ofElestatand, ofElestatandRestasisexceeded, ofElestatfor, ofElestathave, ofElestatin, ofProlacria, ofProlacriaand, ofRestasisfor, ofRestasisoutside, ofRestasisto, ofZaditor, ofZaditorcurrently, onProlacriadue, orProlacria, ourProlacriaprogram, owe, palpebral, Panama, PDUFA, penalty, perfume, pharmacovigilance, pleading, PlusTM, pollen, Portugal, prepay, productAzaSite, Prolacria, Prolacriaand, prosecutorial, PTS, quantification, quantify, Quantifying, qui, reborrowed, regardingAzaSite, repaid, repayment, reputation, respectfully, rhinorrhea, Rica, runny, Salvador, scrutiny, sellProlacria, sentence, shareholder, shift, Silicon, SinceProlacria, smoke, sneezing, sought, Spagnardi, Spain, staining, step, stockpile, substantively, supplyAzaSite, Sweden, tablet, tam, temporarily, thatProlacria, theAzaSite, theDuraSite, threshold, toAzaSite, tradename, TRB, trend, UCB, unblind, unblinding, uncured, unpaid, unrecognized, urticaria, usage, User, utilizingDuraSite, Valley, version, Vienna, violate, violation, VISMED, Vistakon, windfall, Winter, withDuraSite, withProlacria, writing, wrongdoing
Removed:
accomplish, accumulation, acknowledged, acuity, administer, aggregation, aid, alternate, Androgen, blood, Brewery, cancer, Cangrelor, cardiopulmonary, Chapel, Chiron, Ciliary, designing, detachment, Deutsche, discover, drainage, duct, Dyskinesia, employed, enhanced, Equivalence, ethically, exclusively, extremely, feel, fill, foregoing, fulfilled, functional, Gregory, Hill, honestly, Imperial, inhibit, inhibition, initially, inserted, intravitreal, irreversibly, Jaffray, jurisdiction, Kirin, lawfully, leadership, macular, morbidity, Mossinghoff, mucin, Orange, originally, partnership, Petula, Piper, planning, platform, Plavix, progressed, publication, purpose, recruit, reflecting, replacement, retina, returned, rubber, separate, shortage, show, skill, Squibb, surgery, synthesizing, tolerated, tool, transaction, UNC, underwriting, University, uridine, visual
Filing tables
Filing exhibits
- 10-K Annual report
- 10.43 Employee Confidentiality, Invention Assignment and Non-compete Agreement
- 10.44 License Agreement by and Between Inspire Pharm. and Faes Farma, S.a.
- 10.45 Loan and Security Agreement
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
ISPH similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (333-114517), Form S-3 (333-141169), Form S-8 (333-130496) and Form S-8 (333-56360) of Inspire Pharmaceuticals, Inc. of our report dated March 15, 2007 relating to the financial statements, management’s assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting, which appears in this Annual Report on Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 15, 2007